Granahan Investment Management - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 184 filers reported holding NEKTAR THERAPEUTICS in Q2 2015. The put-call ratio across all filers is 0.83 and the average weighting 0.1%.

Quarter-by-quarter ownership
Granahan Investment Management ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q4 2017$9,347,000
-19.5%
156,517
-67.6%
0.74%
-24.1%
Q3 2017$11,611,000
+29.3%
483,800
+5.4%
0.97%
+17.0%
Q2 2017$8,977,000
-32.0%
459,201
-18.4%
0.83%
-37.6%
Q1 2017$13,201,000
-40.8%
562,473
-69.0%
1.32%
+73.0%
Q4 2016$22,286,000
-34.9%
1,816,305
-8.9%
0.77%
-31.7%
Q3 2016$34,242,000
+21.5%
1,993,125
+0.6%
1.12%
+9.2%
Q2 2016$28,180,000
-0.1%
1,980,335
-3.5%
1.03%
+0.1%
Q1 2016$28,213,000
-19.6%
2,051,835
-1.5%
1.03%
-15.0%
Q4 2015$35,084,000
+38.0%
2,082,155
-10.2%
1.21%
+53.4%
Q3 2015$25,424,000
-8.2%
2,319,675
+4.8%
0.79%
+0.4%
Q2 2015$27,682,000
+13.5%
2,212,775
-0.2%
0.78%
+12.3%
Q1 2015$24,386,000
-55.2%
2,216,945
-36.8%
0.70%
-56.0%
Q4 2014$54,405,000
+30.9%
3,509,990
+1.9%
1.59%
+23.8%
Q3 2014$41,557,000
-11.8%
3,442,980
-6.3%
1.28%
-6.7%
Q2 2014$47,105,000
+5.2%
3,674,326
-0.5%
1.38%
+14.0%
Q1 2014$44,771,000
+22.2%
3,693,956
+14.4%
1.21%
+28.0%
Q4 2013$36,637,000
+29.2%
3,227,906
+18.9%
0.94%
+25.1%
Q3 2013$28,356,000
-14.9%
2,714,830
-5.9%
0.75%
-21.5%
Q2 2013$33,336,0002,886,2000.96%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q2 2015
NameSharesValueWeighting ↓
Camber Capital Management LP 5,000,000$82,950,0002.19%
MAVERICK CAPITAL LTD 5,678,221$94,202,0001.75%
Rhenman & Partners Asset Management AB 1,000,000$16,590,0001.48%
Goodman Financial Corp 119,198$1,977,0000.92%
Bellevue Group AG 3,632,358$60,261,0000.83%
OSTERWEIS CAPITAL MANAGEMENT INC 477,004$7,914,0000.53%
Parametrica Management Ltd 13,658$226,0000.43%
RICE HALL JAMES & ASSOCIATES, LLC 592,930$9,837,0000.40%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 67,000$1,110,0000.36%
Burleson & Company, LLC 92,836$1,617,0000.31%
View complete list of NEKTAR THERAPEUTICS shareholders